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An excessive tissue response to prosthetic arterial graft material leads to intimal hyperplasia (IH), the
leading cause of late graft failure. Seroma and abnormal capsule formation may also occur after pros-
thetic material implantation. The matricellular protein Thrombospondin-2 (TSP-2) has shown to be
upregulated in response to biomaterial implantation. This study evaluates the uptake and release of small
interfering RNA (siRNA) from unmodiﬁed and surface functionalized electrospun PET graft materials.
ePET graft materials were synthesized using electrospinning technology. Subsets of the ePET materials
were then chemically modiﬁed to create surface functional groups. Unmodiﬁed and surface-modiﬁed
ePET grafts were dip-coated in siRNAs alone or siRNAs complexed with transfection reagents poly-
ethyleneimine (PEI) or Lipofectamine RNAiMax. Further, control and TSP-2 siRNAePEI complex treated
ePET samples were placed onto a conﬂuent layer of human aortic smooth muscle cells (AoSMCs).
Complexation of all siRNAs with PEI led to a signiﬁcant increase in adsorption to unmodiﬁed ePET. TSP-
2 siRNA-PEI released from unmodiﬁed-ePET silenced TSP-2 in AoSMC. Regardless of the siRNAePEI
complex evaluated, AoSMC migrated into the ePET. siRNAePEI complexes delivered to AoSMC from dip-
coated ePET can result in gene knockdown. This methodology for siRNA delivery may improve the tissue
response to vascular and other prosthetics.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction
Arterial bypass grafts fabricated from poly(ethylene tere-
phthalate) (PET) have been used for over 60 years to repair or
replace a diseased segment of artery. PET prosthetic grafts, similar
to grafts comprised of expanded polytetraﬂuoroethylene (ePTFE) or805, Boston, MA 02215, USA.
ston, MA 02215, USA. Tel.: þ1
(L.K. Pradhan-Nabzdyk),
r Ltd. Open access under CC BY-NC-SApolyurethane, fail due to thrombosis and anastomotic intimal hy-
perplasia (AIH) at the distal anastomosis [1,2]. AIH still remains as
the leading cause for delayed prosthetic bypass graft failure [3,4].
Currently, there are no treatments proven to effectively ameliorate
the pathologic hyperplasia that occurs at the prosthetic graft-
arterial anastomosis [3,4]. Efforts to study gene expression of AIH
using microarray analysis of hyperplastic lesion suggests that the
majority of gene expression changes in the neointimal cells occur
within the ﬁrst week of implantation [5]. Moreover, seroma and
abnormal capsule formation can occur after prosthetic material
implantation, which may compromise the implant.
The expression of one gene in particular, Thrombospondin-2
(TSP-2), increased after one week and was sustained over a 30-
day period of graft implantation [6]. TSP-2 is an anti-angiogenic
matricellular protein. However, not all its functions are yet
known. We have previously shown that TSP-2 regulates smooth
muscle cell attachment [3]. Others have shown that TSP-2 license.
Table 2
siRNA/transfection solutions tested for dip coating.
No transfection reagent RNAiMax PEI N/P ¼ 10
Unlabeled control siRNA 
siGLO Red   
Chol-siRNA   
C.S. Nabzdyk et al. / Biomaterials 35 (2014) 3071e30793072inhibition increases vascularity in granulation and capsular tissue
that forms in response to implanted materials [7,8].
Small interfering RNA (siRNA) is a versatile tool that has the
potential to modulate vascular cell gene expression in a temporary
manner without the potential adverse effects associated with len-
tiviral or adenoviral vectors [9e15]. Previous studies have shown
the differential susceptibility of vascular cells to siRNA transfection
with vascular smooth muscle cells being less susceptible than
endothelial cells [16,17]. Vascular smooth muscle cells of the syn-
thetic phenotype are the predominant cells associated with intimal
hyperplasia and therefore a logical target of gene silencing aimed at
diminishing the vascular response to implanted materials. Because
TSP-2 was found to be consistently upregulated at the anastomosis
of biomaterials to a host artery TSP-2 gene was chosen as the gene
target in this proof of principal study.
Electrospinning provides a rapidly growing technique for
controlled ﬁber modiﬁcation as well as new nanocomposite sub-
strates. Several parameters are attributed to the successful forma-
tion of a product by electrostatic means [18]. These include: 1) the
magnitude of the electric potential in relation to the distance be-
tween the emitter and the collector as well as the discharge media,
2) the viscosity of the polymer solution as determined bymolecular
weight and/or percent solids of the solution and 3) the surface
tension at droplet surface as determined by solvent/polymer
interaction. This research proposal builds on the rapid develop-
ment seen in electrospinning over a number of years [19,20],
including those investigating the formation of electrospun tubular
structures [21].
Electrospinning of PET material and siRNA transfection tech-
nology were combined to explore the possibility of using ePET to
deliver siRNA to aortic smooth muscle cells and achieve effective
gene silencing. The goal of this study is to evaluate the uptake,
release and bioavailability of siRNA, in native and complexed forms,
from unmodiﬁed and surface functionalized ePET graft materials.
Our hypothesis is siRNA can be incorporated into an electrospun
material using a simple dip-coating method, be released from the
material and provide targeted knockdown of a speciﬁc gene.
2. Materials and methods
2.1. Conﬁrmation of siRNA transfection from solution, delivery and target mRNA
knockdown
2.1.1. siRNAs and transfection reagents
siRNAs were obtained from Dharmacon (Lafayette, CO) as follows: 1) non-
targeting-non-ﬂuorescent control siRNA (D-001206-13-20), 2) siGLO Red, a
transfection indicator, consisting of non-targeting double stranded siRNA conju-
gated to the red ﬂuorescent probe DyLight547, 3) 30 Cholesterol and a 50 prime
Dy547 tagged non-targeting control siRNA (Chol-siRNA), 4) TSP-2 siRNA and 5) 30
Cholesterol TSP-2 siRNA (Chol-TSP-2 siRNA). Two transfection reagents were pro-
cured: 1) Lipofectamine RNAiMAX (liposomal transfection reagent; Invitrogen,
Carlsbad, CA) and 2) jetPEI (a cationic polymer; Polyplus, Strasbourg, France).
2.1.2. siRNA transfection protocol
Primary human aortic smooth muscle cells (AoSMC) (Lonza, Walkersville, MD)
were cultured in basal medium (LifeLine, Walkersville, MD) enriched with SMCTable 1
siRNA/transfection reagent combinations evaluated for gene silencing in AoSMC.
Transfection reagent
Absent RNAiMAX PEI (N/P ratios: 2.5, 5 or 10)
siRNA for delivery
Unlabeled control siRNA  
siGLO Red   NP: 2.5, 5 and 10
Chol-siRNA  NP: 5 and 10
siRNA for gene knockdown
Unlabeled control siRNA NP: 10
TSP-2 siRNA NP: 10
Chol-siRNA NP: 10
Chol-TSP-2 siRNA NP: 10growth supplements. The cells were maintained at 37 C with 5% CO2. AoSMCs from
passages 4e8 were used in the experiments. AoSMC were seeded at a density of
5000 cells/well in a 96-well plate (Fisher Scientiﬁc, Pittsburgh, PA). After 24 h,
AoSMCs were transfected with conditions described in Table 1. For all transfections,
siRNAwas used in the range of 0.25 mge1.0 mg. All transfection reagents were used as
recommended by the manufacturer. Complexation of siGLO Red or Chol siRNA with
PEI at N/P ratios of 2.5, 5 and 10were evaluated for delivery efﬁcacy (N/P ratio¼ ratio
of moles of amine groups of PEI to moles of siRNA phosphate groups).
2.1.3. Visualization of siRNA delivery
Visualization of AoSMC siRNA delivery was performed using standard ﬂuores-
cence microscopy.
2.1.4. Quantiﬁcation of target mRNA knockdown
Standard qRT-PCR was used to quantify and compare level of TSP-2 RNA tran-
scripts. Primers (Table S2) were obtained from Integrated DNA Technologies (Cor-
alville, IA). For quantitative analysis, target gene levels were normalized to B2M
levels. Gene expression in cells treated with TSP-2 speciﬁc siRNA was measured as
fold change over cells treated with control siRNA.
2.2. Synthesis and characterization of unmodiﬁed and surface functionalized ePET
2.2.1. Electrospinning of ePET materials
Electrospinning of ePET was done by our collaborators using a computer-
automated electrospinning apparatus. PET polymer chips were dissolved in hexa-
ﬂuoroisopropanol (HFIP) andmixed for 48 h on an inversionmixer. After mixing, the
PET solution was perfused at a steady rate. As the polymer solution reached the
needle port, a voltage of þ20 kV was applied. The polymer jet was collected onto a
30 mm mandrel, resulting in the formation of a ﬂat sheet after removal (ePET). The
ePET sheet was then sonicated in absolute ethanol for 30 min followed by a 2-min
sonication in distilled water to remove residual solvent. ePET material was then air-
dried overnight at room temperature in Kimwipes. All ePET materials (unmodiﬁed
and surface modiﬁed) were sterilized using an Anprolene ethylene oxide sterilizer
(25 C, 12 h cycle, 35% relative humidity, 24 h degas).
2.2.2. Surface modiﬁcation of ePET materials
Segments (5 cm  5 cm) were cut from the main ePET sheet. One segment was
placed into 0.5% (w:v) NaOH at 100 C for 30 min followed by a rinse with a copious
amount of distilled water. This process creates carboxylic acid groups within the PET
polymer chain [22]. Another segment of ePET was placed into 50% ethylenediamine
(diluted from concentratewith distilled water) for 6 h at room temperature followed
by an overnight incubation in distilled water and another rinse with distilled water.
This process creates amine groups within the PET polymer chain [23]. Formation of
functional groups was conﬁrmed via dye uptake studies with methylene blue
(carboxylic acid) and acid red 1 (amine).
2.2.3. Evaluation of surface morphology of ePET materials
Scanning electron microscopy (SEM) was used to visualize strand morphology.
PTFE, utilized in peripheral vascular graft materials, served as reference group.
2.3. AoSMC attachment to untreated and surface functionalized ePET
2.3.1. Visualization of AoSMC attachment to ePET
AoSMCs (40,000 cells) labeled with ﬂuorescent cytoplasmic dye, Cell Tracker
Green (Life Technologies, Grand Island, NY), were seeded onto 5 mm  5 mm
DyLight Red containing ePET pieces for 3 h. Standard confocal microscopy was used
to visualize cell attachment. PTFE, as the most common peripheral vascular graft
material served as reference group.Table 3
Combinations of siRNA/transfection solutions used for dip-coating ePET tested for
AoSMC attachment.
No transfection reagent PEI N/P ¼ 10
ePET  
Control siRNA  
Chol-siRNA  
Fig. 1. Conﬁrmation of siRNA delivery and target mRNA knockdown: A) Fluorescent microscope images of AoSMC transfected with Control siRNA, siGLO Red or
Cholesterol (Chol) siRNA complexed without transfection reagent or with RNAiMax or PEI (N/P ratio of 2.5, 5 or 10) (Mag ¼ 10). B) Thrombospondin-2 (TSP-2)
mRNA expression in AoSMC after transfecting with Control siRNA (0.5 mg), TSP-2 siRNA (0.25 mg or 0.5 mg), Chol-siRNA (0.25 mg) or Chol-TSP-2 siRNA (0.25 mg or
0.5 mg) using PEI.
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Segments of untreated and surface-modiﬁed ePET materials (5 mm  5 mm)
were placed onto the bottom of 96 well plates. AoSMCs (40,000 cells) were seeded
on top of each ePET segment and allowed to attach for 3 h. ePET pieces were
removed, rinsedwith PBS and placed in a newwell. An Alamar blue assay, previously
described by our group [11], was performed tomonitor cell attachment and viability.
Direct attachment of AoSMC to the tissue culture plate well in absence of ePET was
used as control. Again, PTFE served as an experimental control.
2.4. Dip-coating ePET materials with different combinations of siRNA (with and
without PEI)
2.4.1. Visualization of siRNA adsorption to dip-coated ePET
Different siRNA and transfection reagent combinations were made according to
Table 2. Segments of untreated ePET and ePET treated with EDA or NaOH
(5 mm  5 mm) were incubated in the respective siRNA solutions at room tem-
perature for 50 min, rinsed with sterile PBS solution (Dulbecco, Radnor, PA), blotted
dry and mounted on microscope slides using SlowFade Antifade Kit (Invitrogen) for
standard confocal microscopy imaging.
2.4.2. Quantiﬁcation of siRNA adsorption to dip-coated ePET
Seven 5  5 mm ePET samples were placed in a 1.5 ml centrifuge tube and
submerged in 100 ml siRNA (2 mg) solution for 45 min. Using a Nanodrop UV-
spectrophotometer, siRNA concentration was measured in the solution before and
after dipping of the ePET pieces. The relative change in siRNA concentration of the
solution after dipping was calculated and expressed as a ratio normalized to the
starting concentration.
2.4.3. Quantiﬁcation of AoSMC attachment to dip-coated ePET
ePET segments (5 mm  5 mm) were dip-coated as described above with
different siRNA and PEI combinations (Table 3). AoSMC (40,000 cells) were seeded
on top of each of ePET piece and allowed to attach from 3 h up to 48 h. After 3 and
48 h, ePET pieces were removed, rinsedwith PBS and placed in a newwell with fresh
media. An Alamar blue assay was performed as previously described to monitor cell
attachment and viability [3].
2.4.4. siRNA uptake from siRNA treated ePET: uptake visualization and target mRNA
silencing quantiﬁcation in AoSMC
siRNA þ PEI dip-coated ePET pieces (5 mm  5 mm) were placed on top of a
conﬂuent layer of AoSMC for 24 h after which cells were harvested for qRT-PCR to
assess level of mRNA knockdown. Visualization of AoSMC siRNA delivery was per-
formed using standard confocal microscopy. Standard qRT-PCR technique was used
to measure TSP-2 gene knockdown.
2.5. Statistical analysis
Each experiment was performed at least three independent times (n ¼ 3). For
quantiﬁcation of AoSMC attachment, siRNA adsorption and qRT-PCR, each treatment
in each experiment was done in duplicate. For multivariate analysis, 2-way ANOVA
was used, with a p < 0.05 considered statistically signiﬁcant.
3. Results
3.1. Conﬁrmation of siRNA delivery and target mRNA knockdown
3.1.1. Delivery of siRNA to AoSMCs
Visualization of AoSMC siRNA transfection was conﬁrmed by
ﬂuorescence microscopy and confocal microscopy (Fig. 1A).
AoSMCs were transfected as described in Table 1. Transfection of
AoSMCs with control siRNA did not result in any visible intracel-
lular ﬂuorescence. Transfection of AoSMCs with siGLO Red in the
absence of a transfection reagent resulted in only minimal deliveryFig. 2. Ultrastructure of ePET: Scanning electron microscopy images of PTFE, untreainto AoSMCs. Complexing siGLO Red with a commercially available
liposomal transfection reagent, RNAiMAX increased siRNA delivery
into AoSMCs. Complexing siGLO Red with the cationic polymer PEI
led to a N/P ratio dependent increase in delivery into AoSMC. Best
transfection results were observed with an N/P ratio ¼ 10. In
contrast, even in the absence of a transfection reagent, there was
signiﬁcant delivery of Chol-siRNA into AoSMCs. However, to ach-
ieve this level of transfection, a higher concentration of Chol-siRNA
(1 mg) was required compared to PEI-complexed Chol-siRNA. Chol-
siRNA complexed with PEI at N/P ratio ¼ 5 led to modest delivery
while N/P ratio ¼ 10 showed signiﬁcantly higher Chol-siRNA de-
livery. An N/P ratio of 10 was deemed optimal for transfection
success and was therefore used in the subsequent experiments.3.1.2. Target mRNA knockdown in AoSMC
To ascertain that AoSMCs are amenable to TSP-2 siRNA delivery
and TSP-2 mRNA knockdown, AoSMCs were transfected with
control siRNA, TSP-2 siRNA, Chol-siRNA or Chol-TSP-2 siRNA
(Fig. 1B). Compared to control siRNA, TSP-2 siRNA (0.5 mg) signiﬁ-
cantly down-regulated TSP-2 mRNA expression (1.0  0 vs.
0.18 0.04, 5.6 fold down-regulation). Similarly, compared to Chol-
siRNA (control), Chol-TSP-2 siRNA (0.25 mg and 0.5 mg) signiﬁcantly
down-regulated TSP-2 mRNA expression (1.0  0 vs. 0.33  0.02
and 0.26  0.04, 3.0 and 3.8 fold down-regulation). These data
suggest that cholesterol modiﬁcation of siRNA might signiﬁcantly
increase transfection delivery and mRNA knockdown efﬁciency.3.2. Morphology of control PTFE and ePET materials
Using SEM, the ultrastructure of untreated ePET was compared
to ePET treated with EDA and with NaOH. PTFE served as a control
vascular prosthetic bypass material (Fig. 2). As expected, signiﬁcant
differences in the ﬁbrous composition of PTFE and ePET were
observed. While PTFE presented with tightly parallel-aligned ﬁber
bundles with little inter-ﬁber space, ePET consisted of a loosely
aligned ﬁber mesh with variable inter-ﬁber spaces and a fairly
homogenous ﬁber diameter. EDA treatment of the ePETmaterial led
to breakage in some of the ﬁbers, whereas the NaOH treatment did
not induce any signiﬁcant morphologic changes.3.3. AoSMC attachment to untreated and treated ePET
3.3.1. Visualization of AoSMC attachment to ePET
Confocal imaging of DyLight 549 containing ePET (Fig. 3A) was
used to visualize ePET ﬁber matrix in three dimensions (3D) and to
characterize AoSMC ingrowth and morphology. AoSMCs inﬁltrated
the ﬁber matrix, while maintaining their spindle shaped pheno-
type. Furthermore, a three-dimensional orientation of AoSMCs
throughout the matrix was observed (Fig. 3B). Fluorescence mi-
croscopy was also performed to examine AoSMC attachment
differently treated ePET. PTFE served as reference material. Highestted ePET and ePET treated with EDA and NaOH, at low and high magniﬁcation.
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treated with EDA materials (Fig. 3C).
3.3.2. Quantiﬁcation of AoSMC attachment to ePET
AoSMC attachment was also quantiﬁed by Alamar blue assay
3 h after seeding AoSMCs onto different materials (Fig. 3D).
Compared to the tissue culture well and PTFE, ePET showedFig. 3. AoSMC attachment to ePET: A) Confocal microscopic image of Dy549 (red ﬂuorescenc
ePET. (Green ¼ AoSMC Cytoplasm and Blue ¼ Nuclei). C) Fluorescent microscopic images of
(Mag ¼ 10). D) Quantiﬁcation of AoSMC attachment to PTFE, ePET, ePET treated with EDA, a
references to color in this ﬁgure legend, the reader is referred to the web version of this arsigniﬁcantly higher attachment of AoSMCs (0.28  0.04 and
0.36  0.02 vs. 0.59  0.05, units in OD). No signiﬁcant differ-
ences were observed between ePET, ePET (NaOH) and ePET
(EDA), although there appeared to be a trend for AoSMCs to
attach less to ePET reacted with NaOH than to ePET or ePET
reacted with EDA. These results suggested that ePET provided a
better surface for cell attachment and viability proﬁle comparede) labeled ePET. B) Confocal microscopic image of AoSMC attachment to Dy549 labeled
AoSMC attachment to PTFE, ePET, ePET treated with EDA and ePET treated with NaOH
nd ePET treated with NaOH after 3 h using Alamar Blue assay. (For interpretation of the
ticle.)
Fig. 4. Dip-coating ePET with different siRNA solutions: A) Confocal microscopic images showing adsorption of Control siRNA, siGLO Red or Chol-siRNA complexed without or with
PEI (N/P ratio of 10) to dip-coated ePET, ePET treated with EDA or ePET treated with NaOH. B) Quantiﬁcation of adsorption of Control siRNA, siGLO Red or Chol-siRNA complexed
without or with PEI (N/P ratio of 10) to dip-coated ePET. C) Quantiﬁcation of attachment of AoSMC to uncoated ePET or ePET dip-coated in Control siRNA, siGLO Red or Chol-siRNA
complexed with PEI after 3 and 48 h.
C.S. Nabzdyk et al. / Biomaterials 35 (2014) 3071e30793076to cells grown on tissue culture plates or PTFE. ePET treatment
with NaOH and EDA did not change cell attachment ability of
ePET.
3.4. Dip-coating ePET in different combinations of siRNA (with and
without PEI)
3.4.1. Visualization of siRNA adsorption to dip-coated ePET
Confocal microscopy was used to visualize siRNA adsorption to
untreated and treated ePET (Fig. 4A). ePET (untreated and surface
functionalized with EDA or NaOH) dip-coated in solution of Control
siRNA showed no ﬂuorescence. Dipping ePET in solution of siGLO
Red or Chol-siRNA in the absence of a transfection reagent led only
to modest adsorption. Dipping ePET in PEI-complexed siGLO Red or
Chol-siRNA solutions signiﬁcantly increased adsorption to un-
treated ePET but not to EDA or NaOH treated ePET. Based on these
ﬁndings, the subsequent experiments were pursued with ePET
coated with PEI-complexed siRNA (N/P ratio of 10).
3.4.2. Quantiﬁcation of siRNA adsorption to ePET
Based on the confocal microscopy results, siRNA adsorption to
ePET dip-coated with Control siRNA, siGLO Red and Chol-siRNA was
quantiﬁed. siRNA concentration was quantiﬁed via measurement of
siRNA in the incubation solution pre and post dipping using UV-spectrophotometer (Nanodrop) and a ratio of before/after concen-
trationwascalculated (Fig. 4B).A ratioof ‘1’ suggests that therewasno
change in siRNA concentration in the solution, indicating siRNA did
not get adsorbed onto thematerial. A ratio of less than1 suggests that
the siRNA concentration in the solution after dipping is lower than in
the beginning of the dipping indicating higher adsorption of the
siRNA to ePET. Control siRNA did not adsorb to ePET in the absence of
PEI (1.05  0.02), while siGLO Red and Chol-siRNA in the absence of
PEI only modestly adsorbed (0.82  0.05 and 0.89  0.09, respec-
tively). Complexing all siRNAs to PEI led to signiﬁcant adsorption to
ePET (Control siRNA ¼ 0.36  0.02; siGLO Red ¼ 0.42  0.03; Chol-
siRNA ¼ 0.27  0.01). These results conﬁrm that complexation of
unmodiﬁed siRNA, siGLO Red and Chol-siRNA with PEI (N/P
ratio¼ 10) signiﬁcantly enhanced adsorption onto the ePETmaterial.
3.4.3. Quantiﬁcation of AoSMC attachment to dip-coated ePET
AoSMC attachment assay suggested that siRNA-PEI coating of
ePET did not interfere with AoSMC attachment at 3 h nor did it lead
to cell loss after 48 h of cell seeding (Fig. 4C).
3.4.4. siRNA transfection and target mRNA knockdown in AoSMC
using dip-coated ePET
Confocal microscopy illustrated that AoSMC attached and grew
into siRNA þ PEI dip-coated ePET (Fig. 5A). Control siRNA coated
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siGLO Red (no PEI) dip-coated ePET only showed minimal red
ﬂuorescence (data not shown). In contrast, exposure of AoSMCs to
siGLO Red þ PEI or Chol-siRNA þ PEI dip-coated ePET resulted in
signiﬁcant siRNA uptake.
3.4.5. Target mRNA knockdown in AoSMC
As in the confocal microscopy imaging studies, ePET dip-coated
with different siRNA combinations of siRNA þ PEI were placed over
a conﬂuent layer of AoSMCs. Exposure of AoSMCs to TSP-2
siRNA þ PEI dip-coated ePET led to a signiﬁcant decrease of TSP-2
mRNA expression compared to control siRNA þ PEI dip-coated
ePET (1.0  0 vs. 0.43  0.15, 0.26  0.07 and 0.37  0.09, fold
expression). Although exposure of AoSMCs to TSP-2 Chol-
siRNA þ PEI dip-coated ePET led to a reduction in TSP-2 gene
expression, it did not reach statistical signiﬁcance (1.0  0 vs.Fig. 5. siRNA delivery and target gene knockdown in AoSMC: A) Confocal microscopic image
complexed with PEI. 40,000 AoSMCs were placed on top of dip-coated ePET for 48 h for tran
transfection. B) Thrombospondin-2 (TSP-2) mRNA expression in AoSMC after transfection wi
or Chol-TSP-2 siRNA (2, 4 or 6 mg) complexed with PEI.0.65  0.12, 0.52  0.08 and 0.60  0.23, fold expression) (Fig. 5B).
These results suggest that transfection via siRNA þ PEI dip-coated
ePET is a feasible approach for gene silencing.
4. Discussion
Thus far, no efﬁcacious approach to the modiﬁcation of the
vascular response to implanted biomaterials has been identiﬁed.
Electrospun PET offers a material that has an extracellular matrix
(ECM)-like structure and expanded surface area. This provides the
opportunity to incorporate therapeutic agents such as siRNA into
the ePET material in order to locally deliver bioactive agents.
siRNA transfection of AoSMC in vitro can be achieved using
various liposomal transfection reagents such as RNAiMax [13,16].
However, given the in vivo liability of liposomal formulations, the
cationic polymer-based transfection reagent PEI was also tested.s of AoSMC transfected with ePET dip-coated in control siRNA, siGLO Red or Chol-siRNA
sfection or dip-coated ePET was placed on top of conﬂuent layer of AoSMC for 24 h for
th ePET dip-coated in Control siRNA (6 mg), TSP-2 siRNA (2, 4 or 6 mg), Chol-siRNA (6 mg)
C.S. Nabzdyk et al. / Biomaterials 35 (2014) 3071e30793078Polyethyleneimine (PEI), which has been used as a siRNA trans-
fection reagent [24], stabilizes siRNA complexes in vivo while
exhibitingminimal local and systemic toxicity [25e27]. The present
study revealed that PEI complexation of siRNA leads to signiﬁcant
gene knockdown in vitro. The data further showed that AoSMCs
quite readily attached to ePET. In fact, three-dimensional AoSMC
inﬁltration was noted throughout the ePET fabric. No signiﬁcant
changes in cell attachment were noted between ePET and its sur-
face functionalized derivatives.
PEI complexation of siRNA resulted in superior siRNA adsorption
to ePET as compared to RNAiMax, a commonly used liposomal
transfection reagent. Confocal microscopy imaging ﬁndings were
conﬁrmed by analyzing siRNA concentrations in coating solutions
before and after dipping of ePET segments. Unlabeled siRNA was
only minimally adsorbed to ePET while siGLO Red and Chol-siRNA
in the absence of a transfection reagent were modestly adsorbed to
ePET, which may be explained by the dye-like properties of the
DyLight 549 group. As seen in the confocal images, complexation of
PEI and siGLO Red or Chol-siRNA signiﬁcantly enhanced siRNA
adsorption, which could be attributed to Van der Waal forces be-
tween the PEI and PET. Interestingly, EDA and NaOH treatment of
ePET did not signiﬁcantly change the siRNA coating results.
AoSMC attachment and viability were not adversely affected by
the presence of the PEI-siRNA coating. Confocal imaging conﬁrmed
siRNA uptake into inﬁltrating AoSMCs both from PEI-siRNA and
PEI-Chol-siRNA coated ePET. However, only in the case of PEI-siRNA
coated ePET did the uptake result in signiﬁcant gene silencing. Our
previous studies demonstrated that a threshold of intracellular
siRNA has to be exceeded to achieve signiﬁcant gene silencing [13].
Also, some of the visualized PEI-Chol-siRNAmay have been trapped
within the cell membrane and did not enter the cytosol. Thus, this
entrapped PEI-Chol-siRNA may not have contributed to the intra-
cellular siRNA pool. While the purpose of cholesterol is to aid in the
cellular uptake of siRNA, the interaction of PEI may have led to
complexes that upon cell entry did not sufﬁciently release the
siRNA into the cytoplasm.
In summary, ePET effectively adsorbs PEI-siRNA using a simple
dip-coating technique. Additionally, this coating does not impair
AoSMC attachment or viability and results in signiﬁcant gene
silencing in the inﬁltrating cells. While PET has been used for de-
cades in various vascular prosthetic devices, the polymer has also
been used as non-absorbable suture material, in prosthetic meshes
for hernia repair and for orthopedic surgery [4,28e41]. Amongst
other complications, seroma and fabric contraction have been
documented after implantation of PET products [34,37,38,42]. Thus,
PEI-mediated siRNA coating of PET may be used to address these
aspects of wound healing and thereby improve biocompatibility
and longevity of medical devices such as hernia meshes and others.
Gelatin has been used to immobilize PEIesiRNA complexes to
alter surface compatibility of vascular stents [10]. In contrast, the
data presented here shows how therapeutic amounts of siRNA can
be deposited on PET based grafts materials after simple complex-
ation with PEI.
In future experiments, maximal siRNA loading dose and release
rate from ePET will be evaluated. Layer-by-layer deposition of PEIe
siRNA complexes as well as partial crosslinking of PEI may repre-
sent additional protocol modiﬁcations that could increase total
siRNA deposition and modulate siRNA release from ePET ﬁbers,
respectively.
5. Conclusion
This report illustrates direct incorporation of therapeutic
amounts of siRNA onto a prosthetic vascular graft material using
PEI without exogenous binder agents. These complexes remainedfunctional and lead to targeted gene silencing in inﬁltrating human
aortic smooth muscle cells. This protocol could be easily transi-
tioned into a clinical setting given its simple technical re-
quirements. The technique could also bemodiﬁed should there be a
need for silencing of multiple target genes simultaneously or a
prolonged siRNA release.
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